Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd-45 in initiating death. 1995

J E de Vente, and C A Kukoly, and W O Bryant, and K J Posekany, and J Chen, and D J Fletcher, and P J Parker, and G J Pettit, and G Lozano, and P P Cook
Department of Medicine, East Carolina University School of Medicine, Greenville, North Carolina 27858, USA.

Protein kinase C (PKC) modulates growth, differentiation and apoptosis in a cell-specific fashion. Overexpression of PKC-alpha in MCF-7 breast cancer cells (MCF-7-PKC-alpha cell) leads to expression of a more transformed phenotype. The response of MCF-7 and MCF-7-PKC-alpha cells to phorbol esters (TPA) was examined. TPA-treated MCF-7 cells demonstrated a modest cytostatic response associated with a G1 arrest that was accompanied by Cip1 expression and retinoblastoma hypophosphorylation. While p53 was detected in MCF-7 cells, evidence for TPA-induced stimulation of p53 transcriptional activity was not evident. In contrast, TPA treatment induced death of MCF-7-PKC-alpha cells. Bryostatin 1, another PKC activator, exerted modest cytostatic effects on MCF-7 cells while producing a cytotoxic response at low doses in MCF-7-PKC-alpha cells that waned at higher concentrations. TPA-treated MCF-7-PKC-alpha cells accumulated in G2/M, did not express p53, displayed decreased Cip1 expression, and demonstrated a reduction in retinoblastoma hypophosphorylation. TPA-treated MCF-7-PKC-alpha cells expressed gadd-45 which occurred before the onset of apoptosis. Thus, alterations in the PKC pathway can modulate the decision of a breast cancer cell to undergo death or differentiation. In addition, these data show that PKC activation can induce expression of gadd45 in a p53-independent fashion.

UI MeSH Term Description Entries
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D007783 Lactones Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure. Large cyclic lactones of over a dozen atoms are MACROLIDES. Lactone
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011493 Protein Kinase C An serine-threonine protein kinase that requires the presence of physiological concentrations of CALCIUM and membrane PHOSPHOLIPIDS. The additional presence of DIACYLGLYCEROLS markedly increases its sensitivity to both calcium and phospholipids. The sensitivity of the enzyme can also be increased by PHORBOL ESTERS and it is believed that protein kinase C is the receptor protein of tumor-promoting phorbol esters. Calcium Phospholipid-Dependent Protein Kinase,Calcium-Activated Phospholipid-Dependent Kinase,PKC Serine-Threonine Kinase,Phospholipid-Sensitive Calcium-Dependent Protein Kinase,Protein Kinase M,Calcium Activated Phospholipid Dependent Kinase,Calcium Phospholipid Dependent Protein Kinase,PKC Serine Threonine Kinase,Phospholipid Sensitive Calcium Dependent Protein Kinase,Phospholipid-Dependent Kinase, Calcium-Activated,Serine-Threonine Kinase, PKC
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J E de Vente, and C A Kukoly, and W O Bryant, and K J Posekany, and J Chen, and D J Fletcher, and P J Parker, and G J Pettit, and G Lozano, and P P Cook
May 1986, FEBS letters,
J E de Vente, and C A Kukoly, and W O Bryant, and K J Posekany, and J Chen, and D J Fletcher, and P J Parker, and G J Pettit, and G Lozano, and P P Cook
April 1999, Experimental cell research,
J E de Vente, and C A Kukoly, and W O Bryant, and K J Posekany, and J Chen, and D J Fletcher, and P J Parker, and G J Pettit, and G Lozano, and P P Cook
June 1986, Biochemical and biophysical research communications,
J E de Vente, and C A Kukoly, and W O Bryant, and K J Posekany, and J Chen, and D J Fletcher, and P J Parker, and G J Pettit, and G Lozano, and P P Cook
April 1995, The Journal of clinical investigation,
J E de Vente, and C A Kukoly, and W O Bryant, and K J Posekany, and J Chen, and D J Fletcher, and P J Parker, and G J Pettit, and G Lozano, and P P Cook
August 1986, Biochemical pharmacology,
J E de Vente, and C A Kukoly, and W O Bryant, and K J Posekany, and J Chen, and D J Fletcher, and P J Parker, and G J Pettit, and G Lozano, and P P Cook
January 1988, Proceedings of the National Academy of Sciences of the United States of America,
J E de Vente, and C A Kukoly, and W O Bryant, and K J Posekany, and J Chen, and D J Fletcher, and P J Parker, and G J Pettit, and G Lozano, and P P Cook
June 2000, Molecular cell biology research communications : MCBRC,
J E de Vente, and C A Kukoly, and W O Bryant, and K J Posekany, and J Chen, and D J Fletcher, and P J Parker, and G J Pettit, and G Lozano, and P P Cook
December 2000, International journal of oncology,
J E de Vente, and C A Kukoly, and W O Bryant, and K J Posekany, and J Chen, and D J Fletcher, and P J Parker, and G J Pettit, and G Lozano, and P P Cook
January 2003, Journal of experimental therapeutics & oncology,
J E de Vente, and C A Kukoly, and W O Bryant, and K J Posekany, and J Chen, and D J Fletcher, and P J Parker, and G J Pettit, and G Lozano, and P P Cook
March 2015, Scientific reports,
Copied contents to your clipboard!